The combination of 92% mucosal bioavailability, daily consistency that injectable protocols cant match, verified cGMP quality from Instamed, and a $99/month price point that makes long-term use realistic makes the choice clear
Although these agents can be used in CKD patients with an eGFR down to 15 mL/min/1.73 m 2 , the safety of GLP-1 receptor agonists in DKD patients with stage 5 CKD needs to be investigated
Eligibility criteria We included RCTs with a duration of intervention of at least 12 weeks that compared tirzepatide at a maintenance dose of 5, 10 or 15 mg once-weekly, administered subcutaneously, with placebo or any other glucose-lowering medication
( A ) Average GLP-1 staining per islet
Advanced Dose 0.5 mg (500 mcg) Reduced-frequency maintenance once target pigmentation reached, used in practice to sustain tanning [3]